Immunology & allergy
Immune system & allergy clinical trials
Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We’re tracking 6,051 recruiting studies in this area right now.
By phase
- Not applicable2,997
- Phase 21,057
- Phase 1792
- Phase 1/Phase 2437
- Phase 3436
- Phase 4234
- Phase 2/Phase 398
Top conditions
- Multiple Sclerosis330
- Multiple Myeloma327
- Asthma193
- Lymphoma178
- Rheumatoid Arthritis132
- Type 1 Diabetes130
- Atopic Dermatitis125
- Systemic Lupus Erythematosus119
- Acute Lymphoblastic Leukemia118
- HIV Infections106
- Chronic Lymphocytic Leukemia95
- Autoimmune Diseases77
- Follicular Lymphoma70
- Rheumatoid Arthritis (RA)68
- Diabetes Mellitus, Type 163
- Hodgkin Lymphoma63
- Leukemia63
- Mantle Cell Lymphoma62
Leading sponsors
- National Institute of Allergy and Infectious Diseases (NIAID)97
- Institute of Hematology & Blood Diseases Hospital, China85
- National Cancer Institute (NCI)74
- Assistance Publique - Hôpitaux de Paris65
- AstraZeneca63
- M.D. Anderson Cancer Center58
- Novartis Pharmaceuticals58
- Mayo Clinic49
- City of Hope Medical Center48
- Memorial Sloan Kettering Cancer Center45
Where studies are running
- California496
- Maryland200
- Alabama178
- Florida149
- Arizona147
- Massachusetts116
- New York116
- Texas112
- Illinois83
- Colorado82
Recruiting studies6,051 total
- NCT07615725Recruiting
Dry Needling for Lower Leg Pain in Multiple Sclerosis
This study tests whether dry needling—a technique using thin needles to treat muscle pain—can help reduce lower leg pain in people with multiple sclerosis. Researchers want to see if this treatment can safely improve pain and function.
Tampa, FloridaAges 18–80 - NCT07620275RecruitingPhase 1
Cell therapy for multiple myeloma that has come back
This trial tests a new cell therapy (KSVCBD) for people with multiple myeloma that has returned or not responded to other treatments. It may help if your cancer cells have certain markers, CD19 or BCMA.
Beijing, Beijing MunicipalityAges 18–75 - NCT07612319Recruiting
Romiplostim injection for treatment-resistant ITP
This trial tests romiplostim, a weekly injection, for patients with ITP (a blood disorder where the body destroys its own platelets) who did not respond to or could not tolerate oral medications. It aims to help raise platelet counts and reduce bleeding risk.
Suzhou, JiangsuAges 18 years+ - NCT07614633Recruiting
Understanding Eosinophilic Esophagitis Over Time
This study follows patients with eosinophilic esophagitis (a condition where too many white blood cells called eosinophils build up in the food tube) to understand how the disease changes over time and what happens with different treatments. By tracking your symptoms and test results, doctors hope to learn how to better manage this condition.
Pavia, PaviaAges 5 years+ - NCT07617519Recruiting
Remote monitoring for diabetes care at Steno Center
This study looks at how remote patient monitoring—tracking your diabetes from home using technology—changes the care you receive at Steno Diabetes Center Copenhagen. Researchers will compare your care before and after the monitoring system is introduced to see if it helps improve outcomes.
HerlevAges Any age - NCT07617285RecruitingPhase 1
CAR-T cell therapy for relapsed or refractory acute myeloid leukemia
This trial tests a new type of cell therapy called CAR-T, which uses specially engineered immune cells to target acute myeloid leukemia (AML) that hasn't responded to standard treatment. The goal is to see if this therapy can help patients whose cancer has come back or stopped responding to chemotherapy.
BeijingAges 18–70 - NCT07617740RecruitingEarly Phase 1
IASO207 cell therapy for treatment-resistant lupus
This early-stage trial tests IASO207, a new cell therapy designed to help people with severe lupus that hasn't improved with standard medications. The therapy works by modifying immune cells to reduce lupus activity.
BeijingAges 18–75 - NCT07616700RecruitingPhase 2
Long-term safety study of HSK39297 for IgA kidney disease
This study continues treatment with an experimental medicine called HSK39297 for people with IgA nephropathy, a condition where the immune system damages the kidneys. The trial will track how safe and effective the medicine is over time in people who already completed an earlier study.
BeijingAges Any age - NCT07614477RecruitingPhase 2
Testing EVER001 for kidney protein-loss diseases
This study tests a new drug called EVER001 to see if it can reduce protein loss in urine and improve kidney function in patients with specific kidney diseases (FSGS, MCD, or IgAN). These are autoimmune kidney conditions that cause the kidneys to leak protein into the urine.
Beijing, Beijing MunicipalityAges 18–75 - NCT07616089RecruitingPhase 1
Study of a new pill for advanced blood cancers
This trial tests a new pill for people with certain blood cancers that have not gotten better with standard treatments. It aims to see if the drug is safe and works, and it may help shrink tumors or slow the cancer.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07614191RecruitingEarly Phase 1
GT801 Cell Therapy for Hard-to-Treat Autoimmune Diseases
This early-stage study tests a new cell-based treatment called GT801 for autoimmune diseases that haven't responded well to standard medicines. It aims to see if this approach is safe and helps reduce symptoms in conditions like lupus, vasculitis, and scleroderma.
Shanghai, Shanghai MunicipalityAges 18–65 - NCT04191395Recruiting
Study of treatments for long-term inflammatory diseases
This study looks at how chronic inflammatory illnesses progress over time and how treatments affect symptoms and disease markers. You may be invited if you’re receiving care for certain bowel, joint, or skin inflammatory conditions at the hospital.
BesançonAges 18 years+ - NCT06708507Recruiting
Immune cells in graft-versus-host disease
This study looks at special immune cells in the body that may be involved in graft-versus-host disease (GVHD), a complication after a stem cell transplant. The goal is to better understand these cells to improve future treatments for GVHD.
Guangzhou, Other (Non U.s.)Ages 18–65 - NCT06708780RecruitingPhase 1
Treg cell therapy for type 1 diabetes
This trial tests whether giving your own regulatory T cells (a type of immune cell) back to you can help slow or stop the immune attack on your pancreas in type 1 diabetes. It is for people aged 8 to 65 who still make some insulin.
Nanjing, JiangsuAges 8–65 - NCT03976245RecruitingPhase 4
Tested new advanced treatment options for rheumatoid arthritis
This trial studies advanced medicines for rheumatoid arthritis (RA) in people whose RA is still active despite several standard treatments. It may help by testing whether a different advanced option can better control symptoms and joint inflammation.
London, OntarioAges 18 years+ - NCT03888924RecruitingPhase 2
BCG vaccine for people with radiologically isolated syndrome
This trial tests whether a BCG vaccine can help people who have radiologically isolated syndrome (RIS), a condition where MRI scans show signs of possible multiple sclerosis before symptoms develop. The study aims to see if vaccination is safe and can change disease behavior over time.
RomeAges 18 years+ - NCT05820802Recruiting
Studying immune cells in children during surgery
This study looks closely at immune cells in children while they are having surgery under general anesthesia using a specific muscle-relaxing medicine (rocuronium). It may help researchers understand how immune systems respond around the time of surgery and anesthesia.
SeoulAges 2–18 - NCT05957055RecruitingPhase 2
ADHD medicine compared for kids with type 1 diabetes
This Phase 2 study compares two ADHD medicines—lisdexamfetamine and methylphenidate—in children who have ADHD and type 1 diabetes. It’s designed to see which option works better and is safe/effective for managing ADHD without causing major problems for diabetes care.
Lodz, Łódź VoivodeshipAges 8 years–16.5 years - NCT06245629Recruiting
Comparing two drug combos for relapsed multiple myeloma
This trial looks at two different drug combinations given before a second stem cell transplant for multiple myeloma that has come back after first treatment. It aims to see if adding two extra drugs (bortezomib and bendamustine) to the standard drug (melphalan) works better than using the standard drug alone.
UppsalaAges 18 years+ - NCT06509334RecruitingPhase 2
Study of JYB1904 for chronic hives
This trial tests a new medicine, JYB1904, for people with chronic hives (itching and welts) that haven't been controlled by standard allergy pills. It aims to see if JYB1904 can reduce itching and hives better.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06709690Recruiting
AI-powered PET/MR scanner for children with suspected cancer
This study tests a new, fast, and quiet AI-powered PET/MR scanner to take detailed pictures of children with suspected cancer. It aims to make the imaging experience easier and more comfortable for kids.
Shanghai, Shanghai MunicipalityAges Up to 18 years - NCT06709092Recruiting
Testing Lupatadine for dust mite allergies
This study tests a new tablet (Lupatadine Fumarate) for people with nasal allergies caused by dust mites. It looks at how well the medicine works and what it does in the body.
Nanjing, JiangsuAges 18–65 - NCT07611435RecruitingPhase 2
Testing a Safe Control for Alpha-Gal Syndrome Food Challenges
This study helps researchers understand the best way to safely test whether people with alpha-gal syndrome (an allergy to red meat) can tolerate pork. You'll undergo a controlled food challenge with medical supervision and access to emergency medications.
Little Rock, ArkansasAges 12–50 - NCT07605416RecruitingPhase 2
Testing New Drug Combination for Plasma Cell Leukemia
This study tests a new combination of medicines to treat plasma cell leukemia, a rare blood cancer. The trial aims to help patients newly diagnosed with this condition by using drugs that work against cancer cells in different ways.
New Haven, ConnecticutAges 18–80
Common questions
- How many immune system & allergy clinical trials are recruiting?
- Clin2 is tracking 6,051 recruiting immunology & allergy studies from the U.S. registry right now, out of 9,083 we cover in this area in total.
- What does “Immune system & allergy” cover here?
- Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We group each study into immune system & allergy based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a immune system & allergy trial near me?
- Use the search to filter immune system & allergy studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.